INVESTORS

MusclePharm Appoints Daniel Clark as UK Sales Director

Download PDF

New Hire Marks Strategic Push into the UK and Western European Markets

DENVER and LONDON, May 8, 2017 /PRNewswire/ -- MusclePharm Corporation (OTCQB: MSLP) ("MusclePharm" or the "Company"), a scientifically-driven, performance lifestyle sports nutrition company, announced today that Daniel Clark will join the Company as the United Kingdom Sales Director, where he will lead the sales and marketing efforts for the region.

Prior to joining MusclePharm, Mr. Clark served in various roles for six years at USN UK, a global sports supplement company, where he was integral in making it one of the most trusted brands in fitness nutrition. Most recently, he served as the Sales Director at USN where he was responsible for creating, managing and leading a team to manage key national accounts across health, retail, grocery, vending, online and wholesale sectors. While at USN, he successfully spearheaded its expansion into new markets in both the gym and specialist retail sectors, developing a network of national health club operators where he implemented promotional, educational and marketing strategies to establish a strong brand presence. His strategies resulted in the creation of new business channels across multiple sectors.

"The U.K. represents a tremendous growth market for MusclePharm, as the sports nutrition sector is expected to achieve double digit growth year-over-year," said Ryan Drexler, CEO, MusclePharm. "We understand that the nutritional supplements market differs widely from region to region and in order to succeed in the UK, we require someone with institutional on-the-ground knowledge of the market.  The combination of Dan's extensive experience working in the fitness and nutritional field in the UK for nearly two decades, combined with his impressive sales and marketing track record, will allow us to capitalize on the tremendous opportunity in the UK and beyond."

MusclePharm's investment in expanding its international footprint efforts is a critical component of its overall strategy to grow its business and to capitalize on its well-honed brand. Today, MusclePharm has a presence in more than 120 countries, but is looking to gain market share in select markets. At the same time, the Company is working to secure local manufacturing capabilities to allow for easier labeling and more efficient fulfillment.

"In addition to MusclePharm's flagship products across the U.K., there is increasing demand for all-natural, plant-based products that we can address with the Company's newly-launched Natural Series," said Mr. Clark. "With the highest quality ingredients, backed by the robust research and development from its Sports Science Institute, MusclePharm is well positioned to quickly become a name brand in the U.K."

About MusclePharm Corporation

MusclePharm® is a scientifically-driven, performance lifestyle company that develops, manufactures, markets and distributes branded nutritional supplements. The Company offers a range of powders, capsules, tablets and gels. Its portfolio of recognized brands includes MusclePharm® Sport Series, Black Label and Core Series, FitMiss™, as well as Natural Series which was launched in 2017. These products are available in more than 120 countries and over 50,000 retail outlets worldwide. The clinically-proven supplements are developed through a six-stage research process utilizing the expertise of leading nutritional scientists, doctors and universities. MusclePharm is the innovator of the sports nutrition industry. For more information, visit http://www.musclepharm.com. To sign up to receive MusclePharm news via email, please visit http://ir.musclepharmcorp.com/email-alerts.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2015, the Company's Quarterly Reports on Form 10-Q and other filings submitted by the Company to the Securities and Exchange Commission, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/musclepharm-appoints-daniel-clark-as-uk-sales-director-300452835.html

SOURCE MusclePharm Corporation


MusclePharm_Corp_bg_tradeshow